Breakthrough
Research
Led by Dr. Fidelis Ndombera (PhD Biochemistry), our research combines proven scientific excellence with cutting-edge AI innovation.
Featured Research
Novel anti-cancer agents with 51 citations - breakthrough research in cancer therapeutics
Research Focus Areas
Addressing Africa's most pressing health challenges through cutting-edge research, AI innovation, and culturally-sensitive solutions that save lives across the continent.
Infectious Diseases Research
AI-powered diagnostics and treatment optimization for malaria, tuberculosis, HIV/AIDS, and neglected tropical diseases affecting 1.7 billion people across Africa.
Genetic Diseases & Precision Medicine
Developing personalized treatments for sickle cell disease, thalassemia, and other genetic conditions using African genomic data and AI-driven therapeutic design.
African Cancer Research
Targeting cervical, liver, and Kaposi sarcoma - the most prevalent cancers in Africa. Developing culturally-appropriate screening and treatment protocols.
Maternal & Child Health
AI-powered prediction and prevention of preeclampsia, hemorrhage, and pregnancy complications. Reducing Africa's maternal mortality rates through early intervention.
Antimicrobial Resistance
Combating drug-resistant TB, malaria, and bacterial infections through AI-designed novel compounds and resistance prediction algorithms.
Digital Health & AI Ethics
Developing culturally-sensitive AI systems that respect African values, languages, and traditions while ensuring equitable healthcare access.
Research Impact Across Africa
Breakthrough Discoveries
Pioneering research in cancer therapeutics, drug development, and biochemical innovations with global impact and recognition.
Pharmacokinetic, physicochemical and medicinal properties of n-glycoside anti-cancer agent more potent than 2-deoxy-d-glucose in lung cancer cells
F Ndombera, G Maiyoh, V Tuei
Journal of Pharmacy and Pharmacology
This groundbreaking study presents a novel n-glycoside anti-cancer agent that demonstrates superior efficacy compared to 2-deoxy-d-glucose in lung cancer cell lines. Our research reveals significant improvements in pharmacokinetic properties and medicinal potential, offering new therapeutic avenues for cancer treatment with enhanced bioavailability and reduced toxicity profiles.
A clickable glutathione approach for identification of protein glutathionylation in response to glucose metabolism
KTG Samarasinghe, DNPM Godage, Y Zhou, FT Ndombera, E Weerapana, YH Ahn
Molecular BioSystems
We developed an innovative clickable glutathione approach that enables precise identification of protein glutathionylation in cellular responses to glucose metabolism. This methodology provides unprecedented insights into redox regulation mechanisms and opens new avenues for understanding metabolic diseases and developing targeted therapeutic interventions.
Carbohydrate-based inducers of cellular stress for targeting cancer cells
FT Ndombera, GC VanHecke, S Nagi, YH Ahn
Bioorganic & Medicinal Chemistry Letters
This research introduces novel carbohydrate-based compounds that selectively induce cellular stress in cancer cells while sparing healthy tissue. Our findings demonstrate a promising therapeutic strategy that exploits metabolic differences between normal and malignant cells, potentially leading to more effective and less toxic cancer treatments.
Anti-cancer agents and reactive oxygen species modulators that target cancer cell metabolism
FT Ndombera
Pure and Applied Chemistry
This comprehensive review examines the role of reactive oxygen species modulators in cancer therapy, focusing on agents that specifically target altered metabolic pathways in cancer cells. The work provides critical insights into the development of next-generation anti-cancer therapeutics with improved selectivity and efficacy.
Revisiting cheminformatics and mechanisms of action of chloroquine and hydroxychloroquine in targeting COVID-19
FT Ndombera
Journal of Bioinformatics and Computational Genomics
During the COVID-19 pandemic, this timely research provided critical analysis of chloroquine and hydroxychloroquine mechanisms through advanced cheminformatics approaches. The study contributed valuable insights into drug repurposing strategies and highlighted the importance of computational methods in rapid therapeutic development during global health emergencies.
The role of infections in the causation of cancer in Kenya
VC Tuei, GK Maiyoh, FT Ndombera
Cancer Causes & Control
This important epidemiological study examines the relationship between infectious diseases and cancer development in Kenya, providing crucial data for understanding cancer etiology in African populations. The research offers valuable insights for developing targeted prevention strategies and improving cancer care across the continent.
Pawanax AI
Drug Discovery
Building on Dr. Ndombera's groundbreaking research, our AI systems accelerate drug discovery from years to months, focusing on African diseases and personalized medicine.
Molecular AI Analysis
Advanced AI models analyze molecular structures, predict drug-target interactions, and identify promising compounds for African diseases.
Target Identification
AI-powered target discovery for neglected tropical diseases, cancer, and infectious diseases prevalent in Africa.
Virtual Screening
Massive virtual compound libraries screened using AI to identify potential drug candidates with optimal ADMET properties.
Synthesis Prediction
AI predicts optimal synthesis routes for drug compounds, reducing development time and costs significantly.
Clinical Trial Optimization
AI-driven patient stratification and trial design optimization for better outcomes in African populations.
African Disease Focus
Specialized AI models trained on African genetic data and disease patterns for personalized medicine.
AI-Accelerated Drug Discovery Pipeline
Target Discovery
AI identifies disease targets
Compound Design
Generate novel molecules
Virtual Screening
AI predicts activity
Optimization
Enhance drug properties
Clinical Ready
Validated candidates
Join the Future of
Drug Discovery
Be among the first 50 researchers to access our revolutionary AI platform.
"This could revolutionize how we approach drug discovery in Africa" - Leading Research Institution
⏰ Early access closes in 30 days
Join Our Research Efforts
We're always looking for research partners, collaborators, and talented researchers to join our team.